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Intimal hyperplasia is the most common cause of
early failure after percutaneous transluminal coro-
nary angioplasty and peripheral revascularization
procedures. Proliferative vascular lesions develop
after insult to the vascular wall and are composed of
dedifferentiated smooth muscle cells (SMCs) and
extracellular matrix.2,6,13,15 Numerous growth fac-
tors released from injured cells in the vascular wall
contribute to the development of these lesions.
Endothelin-1 (ET-1) is a putative factor in the devel-
opment of intimal hyperplasia.7 It is a potent mito-
gen and vasopressor peptide synthesized by
endothelial cells (ECs) and arteries with an intact
endothelium.25 Studies have shown ET-1 to be ele-
vated in animals after balloon angioplasty and with-
in restenotic and atherosclerotic lesions.3,7 Plasma
levels of ET-1 have been shown to be low in healthy
individuals. The EC-SMC interaction within the
healthy vessel wall may contain regulatory mecha-
nisms that suppress ET-1 production. However,
mechanical or biochemical insult to the vessel wall
may alter the physiologic mechanisms that modulate
ET-1 production and activity. 
ET-1 mediates its effect through two cell-surface
ET-1 receptor subtypes. ECs express the ET-1B sub-
type receptor, and SMCs normally express the ET-1A
receptors.1,11,23 After vascular wall injury, however,
SMCs have been shown to express both ET-1B and
ET-1A receptors.1,18 The ET-1A and ET-1B receptors
mediate the vasopressor action of ET-1 on SMCs
through the activation of phospholipase C. The for-
mer results in the formation of diacylglycerol and
inositol 1,4,5-triphosphate. Calcium and diacylglyc-
erol stimulate protein kinase C, which mediates the
mitogenic action of ET-1.18,23 The specific role of
the two receptor subtypes in the development of vas-
cular lesions has not been defined clearly. One goal of
our studies was to determine which receptor subtype
mediates the proliferative response in SMCs. 
ECs have been shown to secrete ET-1 in cul-
ture.25 By using a compartmentalized co-culture
system, we sought to determine whether SMCs
inhibit EC secretion of ET-1. We have previously
shown that ECs stimulate SMC proliferation in
bilayer co-culture, which may be caused by EC-
secreted ET-1. Mechanisms likely exist by which
SMCs regulate EC ET-1 production when these cell
Vascular smooth muscle cell effect on
endothelial cell endothelin-1 production
Gabriele Di Luozzo, MD, Jaya Bhargava, PhD, and Richard J. Powell, MD,
Lebanon, NH
Endothelin-1 (ET-1) is a potent mitogen secreted by endothelial cells (ECs) in culture
and is a putative factor in vascular lesion development. The purpose of this study was to
examine whether smooth muscle cells (SMCs) inhibit EC secretion of ET-1. The effect
of SMCs on EC ET-1 and constitutively expressed nitric oxide (NO) synthase activity
was examined by using a bilayer co-culture model. SMCs inhibited both EC ET-1 pro-
tein and RNA levels, compared with ECs cultured alone. SMCs increased EC NO pro-
duction when compared with ECs cultured alone. In addition, SMC inhibition of EC
ET-1 production could be blocked by the NO synthase inhibitor NG-Nitro-L-arginine-
methyl ester. ECs stimulated SMC proliferation, and the ET-1 AB and B receptor block-
ers inhibited EC stimulation of SMC proliferation. The ET-1 A blocker had no effect
on SMC proliferation. We conclude that SMCs regulate EC ET-1 and ecNOS synthase
transcript levels and protein levels. SMC inhibition of ET-1 production by ECs may be
mediated through SMC-modulated changes in EC NO activity. Finally, EC stimulation
of SMC proliferation in bilayer co-culture is mediated by ET-1 through the ET-1 B
receptor. (J Vasc Surg 2000;31:781-9.)
781
From the Section of Vascular Surgery, Yale University School of
Medicine, and the Section of Vascular Surgery, Department of
Surgery, Dartmouth-Hitchcock Medical Center.
Competition of interest: nil.
Supported by a Veterans Administration Merit Review Grant.
Reprint requests: Dr Richard J. Powell, Section of Vascular
Surgery, Dartmouth Hitchcock Medical Center, One Medical
Center Dr, Lebanon, NH 03756-0001.
Copyright © 2000 by the Society for Vascular Surgery and
International Society for Cardiovascular Surgery, North
American Chapter.
0741-5214/2000/$12.00 + 0 24/1/103788
doi:10.1067/mva.2000.103788
types are near, such as in the vessel wall or in bilayer
co-culture (Fig 1). 
One possible mechanism by which SMCs may
inhibit EC ET-1 secretion is through altering EC
nitric oxide synthase (NOS). Both ECs and SMCs
produce nitric oxide (NO). There are two known
isoforms of NOS. Endothelial cells contain a consti-
tutively expressed form (ecNOS), and both ECs and
SMCs contain an inducible form (iNOS).10 NOS
converts L-arginine to NO. Inhibition of EC NO
production by L-arginine analogs has been shown to
result in an increase in EC ET-1 synthesis.17 NO or
L-arginine administration to animals after vascular
insult has shown to reduce significantly the degree
of neointimal formation and ET-1 synthesis.5,14,17
Increased EC NOS activity could be expected to
downregulate EC ET-1 production. 
In this study, we used a bilayer co-culture system
to test the hypothesis that SMCs inhibit EC ET-1
gene transcript levels and protein production and
that this effect is mediated through upregulation of
EC ecNOS activity. In addition, we examined the
role of EC-secreted ET-1 on SMC proliferation in
bilayer co-culture and identified which ET-1 recep-
tor subtype mediates this proliferative response. 
METHODS
Co-culture model. Bovine aortic ECs and
SMCs were harvested by means of the scraping
method for ECs and the explant method for SMCs.
Cells were grown 4 to 10 passages from primary cul-
tures in low glucose Dulbecco’s Modified Eagles
media (DMEM) in T75 flasks supplemented with
penicillin, streptomycin, glutamine, and 10% calf
serum (CS). Endothelial cells were identified with 
a monoclonal mouse antibody to human von
Willebrand factor (Dako-VWF, F8/86; Dako,
Carpinteria, Calif), and SMCs were identified with an
anti-α-actin antibody (Sigma A-2547; Sigma Chem-
ical, St. Louis, Mo). For each component of this study,
SMC cultures were established by plating cells on a
13-mm thick polyethylene terephthalate membrane
with 0.45-mm pores, configured at a density of 1.6
million pores/cm2 (Cyclopore Membrane, Falcon cell
culture insert; Becton Dickson, Lincoln Park, NJ).
The seeding density of SMCs for the conditioned
media assays was 1.0 × 105/25 mm2. The EC/SMC
bilayer co-culture model has been described in
detail.8,20,21 In brief, co-cultures were established by
plating SMCs opposite confluent ECs. ECs were ini-
tially plated onto the membrane at confluent seeding
densities and examined daily by means of phase con-
trast microscopy. SMCs were then plated onto the
membrane opposite ECs 2 days after ECs attained
confluence. 
The experiments were performed and are report-
ed in the following sequence. The effect of SMCs on
EC ET-1 messenger RNA and protein levels was
examined. This was followed by a measurement of
the SMCs’ effect on EC NO production. Next, the
effect of NOS inhibition on SMC inhibition of EC
ET-1 secretion was determined. Finally, the effect of
EC release of ET-1 on SMC proliferation was mea-
sured, and the ET-1 receptor that mediated this
process was determined.
Radioimmunoassay for endothelin-1. Radio-
immunoassay for ET-1 was performed on conditioned
media with a commercially available kit in a manner
specified by the manufacturer (Endothelin-1; Peninsula
Laboratories, Belmont, Calif). Fresh media with 2.5%
CS was conditioned in the presence of ECs cultured
alone and ECs co-cultured with SMCs. The condi-
tioned media was removed from both sides of the
membrane after 4, 24, 48, and 72 hours of incubation
and was centrifuged to remove cellular debris and kept
at –70°C until assays were performed. Full-strength
conditioned media and ET-1 standards were reconsti-
tuted in assay buffer and incubated with rabbit anti-ET-
1 serum for 24 hours at 4°C. The addition of 100 µL
of [I125]-labeled ET-1 (400 to 500 mCi/mg) was fol-
lowed by a second 24-hour incubation, and bound and
free radioligand were separated by using a second anti-
body. Radioactivity (cpm) was measured with a Gamma
counter. The results were presented as pg/mL/106
ECs. In the experimental conditions used, the detec-
tion limit of the assay was 1 pg of immunoreactive ET-
1 per 100 mL of sample. The ET-1 antibody has a 10%
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Fig 1. The proposed effect of smooth muscle cells (SMC)
on endothelial cell (EC) release of endothelin-1 (ET-1)
and nitric oxide (NO). The mechanism by which smooth
muscle cells cause this is unknown.
cross-reactivity with big ET-1 and 5% with endothelin-
3, but no cross-reactivity with atrial natriuretic factor,
brain natriuretic peptide, vasopressin, or angiotensin I
and II.
Nitric oxide assay. The identical samples and
intervals used in the ET-1 radioimmunoassay were
used to measure NO produced in co-culture and soli-
tary culture models. NO was measured with a com-
mercially available kit (Nitric Oxide Assay Kit;
Calbiochem-Novabiochem, San Diego, Calif), which
uses spectrophotometric quantitation with the Griess
reagent. NO in culture is converted rapidly to nitrates
and nitrites. The Griess reagent does not measure
nitrates; thus, the nicotinamide adenine dinucleotide
phosphate hydrogenase–dependent enzyme nitrate
reductase is used to convert nitrates to nitrites before
measuring nitrite levels with the Griess reagent.
Standards and experimental samples were reconstitut-
ed in assay buffer, and predetermined quantities of
diluted nitrate reductase and NADPH were added to
each well of the microplate, in a manner described by
the manufacturer. Samples were read on spectropho-
tometer at an absorbance reading of 550 nm and
compared with known standards.
Nitric oxide synthase inhibition assays.
Experimental groups were treated with 2.5 mmol/L
of NG-Nitro-L-arginine-methyl ester (L-NAME;
Alexis, San Diego, Calif) to determine whether NO
was involved in regulation of EC ET-1 protein pro-
duction. This concentration was selected because it
was the lowest concentration that maximally sup-
pressed NO production in cultured SMCs, as mea-
sured by means of the Greiss reaction, and also
blocked NOS activity in cultured SMCs, as deter-
mined by means of NADPH diaphorase staining.24a
Conditioned media was changed every 48 hours in
the EC, SMC/EC, and SMC cultured alone groups,
at which time new L-NAME was added. Both ECs
and SMCs were exposed to L-NAME in the co-cul-
ture model. Conditioned media was collected after
cells were maintained in culture for 12, 24, 48, and
72 hours. Full-strength conditioned media, pre-
pared as described previously, was assayed as
described previously for NO (nitrite) and ET-1 pro-
tein production. 
RNA preparation and Northern blot analysis.
Total RNA extraction was performed on ECs in co-
culture or in solitary culture after 4, 24, 48, and 72
hours of culture. Differences in EC RNA expression
for ET-1 and the constitutively expressed isoform of
NOS (ecNOS) were examined by using Northern
blot analysis. In brief, EC total RNA was extracted
with trizol reagent (Gibco BRL, Grand Island, NY)
and a modified method of Chomczynski and Sacchi.
Twenty-five micrograms of total RNA per lane was
fractionated on a 1% formaldehyde agarose gel and
transferred to a genescreen nylon membrane (NEN
Research Product, Boston, Mass). The membrane
was cross-linked by means of ultraviolet light. A 2.4-
kB complementary DNA probe for human ET-1 was
supplied by Dr Masashi Yanagisawa (University of
Tsukuba, Tsukuba, Japan). Labeling was achieved
with the “Ready To Go” DNA Labeling Beads
(dCTP; Pharmacia Biotech, Piscataway, NJ) or a ran-
dom priming method (dCTP; Gibco BRL, Grand
Island, NY) and Redivue 32P dCTP (Amersham,
Arlington Heights, Ill). Labeled probes were purified
by means of Sephadex G-50 fine spin columns.
Hybridization was performed at 42°C for 24 hours in
a solution containing 50% formamide, 6.6× sodium
chloride sodium citrate (SSC), 0.1% sodium dodecyl
sulfate (SDS), 5× denhardt’s solution, 200 µg/mL
salmon sperm DNA, 0.5 mol/L EDTA, and auto-
claved double distilled water. Conditions of high strin-
gency were established by washing the membrane and
soaking twice at 42°C for 30 minutes in a solution of
0.1% SDS and 1× SSC. Blots were exposed to Biomax
MS film (Kodak) at a temperature of –70°C with
intensifying screens. Blots were then stripped with
0.1% SDS and reprobed with glyceraldehyde phos-
phate dehydrogenase (GAPDH) to quantitate for lane
loading. Signals were measured by means of densito-
metry in the linear portion of development and stan-
dardized to GAPDH. Results are presented as per-
centage of the control (ECs cultured alone at 4 hours).
Proliferation and endothelin-1 receptor
antagonist studies. Previous work from our labora-
tory and other laboratories has shown that ECs stim-
ulate SMC proliferation. We sought to determine
whether ET-1 secreted by ECs was responsible for
this. SMCs (1.0 × 103 cells/25mm2) cultured alone
were compared with SMCs cultured opposite ECs.
Twenty-four hours after plating, 10% CS DMEM
was removed, and 2 mL of 2.5% CS DMEM was
added to each side of the membrane. We used 2.5%
CS, because we found that this concentration of CS
results in half maximal stimulation of proliferation.
After 24 to 72 hours in culture, the SMCs were
removed from the membrane by means of trypsiniza-
tion (Gibco BRL, Grand Island, NY). SMC counts
were determined by counting aliquots of trypsin-
treated cell suspensions with a Coulter counter
(Coulter Electronics, Hialeah, Fla).
SMCs in each group were then treated with 0.1
to 25 mmol/L of either ET-1 receptor A+B anta-
gonist (PD145065; Sigma Chemical), ET-1 recep-
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tor A antagonist (BQ-610; Peninsula Laboratories,
Belmont, Calif), or ET-1 receptor B antagonist
(IRL-1038; Peninsula Laboratories, Belmont,
Calif). Cell counts of SMCs cultured alone were
compared with co-cultured SMCs in the presence
and absence of the various ET-1 receptor blockers.
Statistical analysis. Each experiment (4 to 6 wells
per experiment) was performed in triplicate. Data are
presented as the mean plus or minus the SEM of a rep-
resentative experiment, except where noted, in which
case data have been pooled and are presented as a per-
centage of the control. Statistical significance between
groups was determined by means of analysis of vari-
ance and post hoc Tuckey test with commercially avail-
able software (Systat, Evanston, Ill) and a Macintosh
Power PC 7200/90 personal computer. Significance
was defined as a P value less than .05.
RESULTS
Effect of smooth muscle cells on endothelial
cell endothelin-1 protein expression.  SMCs
inhibited EC ET-1 production 4 hours after co-cul-
ture and continued to do so through the last point
studied at 72 hours (Fig 2). When data from all
experiments were pooled, SMCs inhibited EC ET-1
protein expression at 4, 24, 48, and 72 hours by 60%
± 9%, 61% ± 8%, 92% ± 4%, and 95% ± 2%, respec-
tively, when compared with ECs cultured alone.
Effect of smooth muscle cells on endothelial
cell endothelin-1 messenger RNA expression.
ET-1 RNA levels in ECs co-cultured with SMCs
were decreased as early as 24 hours, when compared
with ECs cultured alone (Fig 3A and B). The
decrease in co-cultured EC ET-1 RNA levels persist-
ed for as long as 72 hours in co-culture. During this
period, there is minimal direct cell-to-cell contact
across the semipermeable membrane. Thus, the
SMC inhibition of EC ET-1 RNA levels and protein
production is mediated by a diffusable molecule.
Effect of nitric oxide inhibition on smooth
muscle cell suppression of endothelial cell
endothelin-1 production. The inhibition of NO
levels in both ECs and SMCs during coculture
resulted in a significant increase in ET-1 production
(Fig 4). SMCs cultured alone or in the presence of
the NO inhibitor L-NAME had minimal ET-1 levels
in the conditioned media. The increase in ET-1 in
co-culture after NO inhibition is likely a result of
increased EC ET-1 production and is not from
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Fig 2. Smooth muscle cells significantly inhibit endothelial
cell (EC) endothelin-1 (ET-1) levels in co-culture (smooth
muscle cells/endothelial cells). At intervals of 0, 4, 24, and
48 hours, the total endothelin-1 protein level in the condi-
tioned media of co-cultured endothelial cells (dashed line)
is decreased, compared with the total endothelin-1 protein
level in endothelial cells cultured alone (solid line; repre-
sentative experiment, *P < .05, n = 6/experiment).
Fig 3. A, Representative Northern blot analysis of endothe-
lin-1 (ET-1) RNA levels from endothelial cells (EC) cul-
tured alone and co-cultured endothelial cells at intervals of
4, 24, 48, and 72 hours. Lane loading was determined with
GAPDH. B, Densitometry of four experiments shows a
decrease in endothelin-1 transcript levels in endothelial cells
cultured opposite smooth muscle cells (SMC; dashed line),
compared with endothelial cells cultured alone (solid line),
at 48 and 72 hours (*P < .05, n = 3).
A
B
SMCs. Similarly, ECs cultured alone had a modest
17% increase in ET-1 production in the presence of
the NO inhibitor L-NAME. A dose-response rela-
tionship existed between an increase in L-NAME
dose and an increase in ET-1 in co-cultured ECs
(Fig 5). The effect of L-NAME on suppression of
SMC inhibition of EC ET-1 protein production was
reversible. Forty-eight hours after removal of L-
NAME from the co-culture media, ET-1 levels were
again decreased, compared with ECs cultured alone
(data not shown). NO inhibition in the EC-SMC
bilayer co-culture system blocked the inhibitory
effect of SMCs on EC ET-1 production. 
Smooth muscle cell effect on endothelial cell
nitric oxide expression. We have shown that NO
inhibition in EC-SMC bilayer co-culture prevents
SMC inhibition of EC ET-1 production. We next
sought to determine whether SMCs regulate EC NO
expression. After 48 hours in co-culture, ECs had an
approximately five-fold increase in NO levels in the
conditioned media, compared with ECs cultured
alone (Fig 6). The NO measured in the conditioned
media of co-cultured ECs could originate from the
ECs themselves or may have originated from SMCs
and simply crossed the semipermeable membrane.
SMCs co-cultured opposite ECs did not contain
active inducible NOS (iNOS), because they did not
stain with NADPH diaphorase (Fig 7). SMCs cul-
tured alone did contain iNOS, as demonstrated by
means of blue staining in the presence of NADPH
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Fig 4. Inhibition of nitric oxide synthase activity with 2.5
µmol/L of NG-Nitro-L-arginine-methyl ester (L-NAME)
resulted in a significant increase in endothelin-1 (ET-1)
levels in co-cultured endothelial cells (SMC/EC+L-
NAME), compared with co-cultured endothelial cells
without NG-Nitro-L-arginine-methyl ester (SMC/EC),
after 48 hours in culture. The addition of NG-Nitro-L-
arginine-methyl ester to endothelial cells cultured alone
(EC+L-NAME) resulted in an increase in endothelin-1
protein levels, compared with endothelial cells cultured
alone (EC), but this was not significant (representative
experiment, n = 6/experiment). 
Fig 5. Dose response of NG-Nitro-L-arginine-methyl
ester (L-NAME) on endothelial cell endothelin-1 (ET-1)
protein levels. Endothelial cells cultured alone are shown
in the solid line, and co-cultured endothelial cells are
shown in the dashed line (*P < .05).
Fig 6. Smooth muscle cell effect on endothelial cell nitric
oxide (NO) production after 48 hours in culture.
Endothelial cells cultured alone (EC, black bar) had sig-
nificantly lower levels of nitric oxide, compared with
endothelial cells co-cultured with smooth muscle cells
(SMC/EC, black bar). Shown in hatched bars is the effect
of 2.5 µmol/L of NG-Nitro-L-arginine-methyl ester.
diaphorase. iNOS expression in SMCs cultured alone
was inhibited with L-NAME, because these cells
failed to stain with NADPH diaphorase. The absence
of NADPH diaphorase staining in co-cultured SMCs
suggests that SMCs likely do not contribute to the
increase in NO present in co-culture and that the
increase in NO is originating from ECs. Thus, most
of the increased NO in the co-cultured conditioned
media likely originated from the ECs.
Effect of endothelin-1 receptor antagonists on
smooth muscle cell proliferation. ECs increased
SMC proliferation by 50% ± 11% to 105% ± 18% (P
< .05) in the co-culture model, as compared with
SMCs cultured alone (Fig 8A to C). The ET-1 AB
receptor antagonist (PD145065) inhibited the prolif-
eration of SMCs in co-culture by 64% ± 4% (P < .05)
and SMCs in solitary culture by 27% ± 8% (P = .46;
Fig 8A). The ET-1 A receptor antagonist (BQ-610)
did not have a significant effect on SMC proliferation
in either culture model (Fig 8B). Endothelial cell
stimulation of SMC proliferation was inhibited by
the ET-1 B receptor antagonist by 72% ± 13% (P <
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Fig 7. A, NADPH diaphorase stain of smooth muscle cells cultured alone. B, NADPH
diaphorase stain of smooth muscle cells cultured opposite endothelial cells.
A
B
.05; Fig 8C). The proliferation of SMCs cultured
alone in the presence of the ET-1 (B) receptor antag-
onist was inhibited by 50% ± 3% (P < .05).
DISCUSSION
In this study, ET-1 production by ECs was inhib-
ited when cultured opposite SMCs. This finding is
similar to that of Stewart and co-workers, who
showed that both SMCs and fibroblasts inhibit
bovine pulmonary EC release of ET-1. These
authors showed that an as-yet-unidentified diffus-
able substance was responsible for this effect.24 In
addition, these authors showed that ET-1 clearance
was unchanged in co-cultured cells. Our study has
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Fig 8. A, Compared with smooth muscle cells cultured alone (SMC), endothelial cells stimu-
lated proliferation of co-cultured smooth muscle cells (SMC/EC) by 105%. The endothelin-1
AB receptor antagonist (PD145065) inhibited proliferation of smooth muscle cells cultured
alone (SMC+AB) by 27% (P = 0.46, SMC+AB vs SMC group) and inhibited co-cultured
smooth muscle cell proliferation (SMC/EC+AB) by 64%. B, Compared with smooth muscle
cells cultured alone (SMC), endothelial cells stimulated proliferation of co-cultured smooth
muscle cells (SMC/EC) by 72%. The endothelin-1 A receptor antagonist (BQ-610) did not
inhibit smooth muscle cell proliferation of smooth muscle cells cultured alone (SMC+A) or co-
cultured smooth muscle cells (SMC/EC+A). C, Compared with smooth muscle cells cultured
alone (SMC), endothelial cells stimulated proliferation of co-cultured smooth muscle cells
(SMC/EC) by 105%. The endothelin-1 B receptor antagonist (IRL-1038) inhibited prolifera-
tion of smooth muscle cells cultured alone (SMC+B) by 50% and inhibited co-cultured smooth
muscle cell proliferation (SMC/EC+B) by 72%.
A
B C
additionally shown that SMCs suppress both EC
ET-1 gene expression and protein production in a
bovine aortic EC line. In addition, we have shown
that SMCs have an opposite effect on EC NO pro-
duction. The mechanism by which SMCs stimulate
EC ecNOS expression and NO production is
unclear. However, this may be an important mecha-
nism by which SMCs regulate EC ET-1 production.
When increased NOS activity that was observed in
ECs co-cultured with SMCs was blocked with L-
NAME, a marked increase in ET-1 protein levels
resulted, compared with that of ECs cultured alone.
Thus, one possible mechanism by which SMCs
inhibit EC ET-1 production is mediated through
increasing EC ecNOS activity. These data are similar
to those of Flowers and co-workers, who have
shown a reciprocal regulation of EC ET-1 and
ecNOS expression in proliferating ECs.10
In the present study, the inhibitory effect of
SMCs on EC ET-1 protein secretion preceded
decreased gene expression by 24 to 48 hours. This
could be either related to the relative sensitivities of
the protein assay and Northern blot analysis or
caused by several mechanisms of inhibition that
result in early protein inhibition followed by gene
suppression. 
Our data suggest that the SMC effect is mediat-
ed through a soluble factor, because minimal cell-to-
cell contact occurred across the membrane during
the period in which these studies were conducted.
Co-culture conditions have a profound impact on
the SMC inhibition of EC ET-1 production. In co-
culture experiments in which EC contact is minimal,
such as our bilayer co-culture model or the micro-
carrier bead technique of Stewart and co-workers,24
SMCs have a sustained inhibitory effect on EC ET-
1 production. On the other hand, Bonin and
Damon, using a monolayer co-culture model that
results in widespread intimate SMC-EC contact,
have shown that SMCs transiently stimulate EC ET-
1 gene transcription and protein secretion for as
long as 24 hours, before returning to baseline lev-
els.4 These authors have shown that the SMC stim-
ulatory effect on EC ET-1 production is mediated
by a transient increase in transforming growth factor
(TGF)–β1 activation known to occur in monolayer
co-culture.16,22 Similarly, Komatsu and co-workers
have shown that SMCs stimulate EC C-type natri-
uretic peptide in monolayer co-culture, which is
again a result of increased TGF-β1 activation.12 We
have chosen the bilayer co-culture model because it
may be more physiologically relevant, compared
with other co-culture systems. In the bilayer model,
SMCs are separated from ECs by means of a semi-
permeable membrane that allows for cell-to-cell
contact, but not to the degree that occurs in mono-
layer co-culture. Extensive EC-SMC contact has
been shown to result in increased TGF-β1 activation
and an increase in ET-1 production, both of which
could lead to the development of vascular lesions. In
addition, in the bilayer model, SMCs are exposed to
the abluminal surface of ECs, similar to that which
occurs in the in vivo state. Despite the apparent
advantages of the bilayer co-culture system, it does
not replicate the in vivo situation exactly. The
absence of various matrix components, inflammato-
ry cells, and shear and pulsatile strain suggests that
these data cannot automatically be extrapolated to
what occurs in vivo. 
Increased release of ET-1 by ECs cultured alone,
with its potential mitogenic effects on SMCs, seems
counterintuitive to what is thought to occur in the in
vivo state. Increased ET-1 production by ECs in vitro
may be an artifact of tissue culture. However, recent
reports have shown that ET-1 maintains cultured
SMCs in a contractile phenotype.9 In addition, ET-1
has been shown to decrease SMC iNOS activity.11a
This is supported by data in the present study, in
which ECs decreased SMC iNOS activity, as mea-
sured by means of NADPH diaphorase staining.
Increased iNOS activity has recently been shown to
promote atherosclerosis progression in transplant
patients and may be important in SMC dedifferenti-
ation into the synthetic phenotype. Thus, tonic low
levels of ET-1 may be important in maintaining
SMCs in a contractile phenotype in the healthy unin-
jured arterial wall. SMC inhibition of EC ET-1 pro-
duction may be a regulatory mechanism to prevent
excess ET-1 production, which would likely result in
the development of vascular lesions. SMCs appear to
closely regulate not only EC ET-1 production, but
also NO production, and SMC regulation of EC
function plays an important and underappreciated
role in preventing the development of proliferative
vascular lesions in the arterial wall.
We and other investigators have shown that ECs
stimulate SMC proliferation when these cell types
are co-cultured as a bilayer.8,20,21 In the present
study, we have shown, as other studies have previ-
ously, that ECs constitutively express ET-1 in cul-
ture.24 By using ET-1 receptor antagonists, we have
shown that EC production of ET-1 appears to be
responsible for the increase in SMC proliferation
observed in co-cultured cells.
We used selective ET-1 receptor antagonists to
determine which receptor subtype mediates the SMC
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proliferative response that occurs when ECs are co-
cultured with SMCs. The use of ET-1A+B receptor
antagonist (PD145065) reduced the proliferation of
SMCs significantly in solitary and in co-culture. The
ET-1A receptor antagonist (BQ-610) only minimally
reduced SMC proliferation in either culture model.
IRL-1038, the ET-1B receptor antagonist, inhibited
SMC proliferation markedly in co-culture and soli-
tary culture. The combination of IRL-1038 and BQ-
610 inhibited SMC proliferation in a manner similar
to that of SMCs treated with IRL-1038 alone (data
not shown). The present study indicates that the EC
mitogenic effect on SMCs is mediated predominate-
ly via ET-1 and the ET-1B receptor. The ET-1A
receptor had a minimal role in stimulating SMC pro-
liferation in vitro. The temporal increase in the ET-
1B receptor messenger RNA transcription that is
known to occur after arterial injury is likely to coin-
cide with an increase in ET-1 released from injured or
proliferating ECs after percutaneous transluminal
coronary angioplasty. This could then set the stage
for the development of a proliferative vascular lesion.
In conclusion, we have shown that ECs stimulate
SMC proliferation in vitro. The mitogen responsible
for SMC proliferation in co-culture is ET-1. The
proliferative effect of ET-1 on SMCs is predomi-
nately through the ET-1B receptor. In addition, EC
ET-1 RNA levels and ET-1 secretion are inhibited
and ecNOS gene expression and NO levels are stim-
ulated when cultured opposite SMCs. SMCs may
have an important role in regulating ET-1 and NO
production in the arterial wall.
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